MedTrace Logo

Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis

NCT02341378 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2015-01-22

No results posted yet for this study

Summary

To assess the efficacy and safety of the intra-articular injection of TissueGene-C in patients with degenerative arthritis of the knee

Conditions

  • Degenerative Arthritis

Interventions

BIOLOGICAL

TissueGene-C(Low dose)

TissueGene-C at 6.0x10\^6 cells

BIOLOGICAL

TissueGene-C(High dose)

TissueGene-C at 1.8x10\^7 cells

Sponsors & Collaborators

  • Kolon Life Science

    lead INDUSTRY

Principal Investigators

  • Chul-won Ha, MD, PhD · Samsung Medical Center

  • Myung-chul Lee, MD, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-06-30
Completion
2010-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02341378 on ClinicalTrials.gov